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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is
Afrin (Oxymetazoline) a safe and effective drug in normal, healthy adults with reference to nasal
congestion and the nasal response?”
STUDY DESIGN: Review of three English language primary studies published in 1997, 1999,
2003.
DATA SOURCES: Randomized, controlled studies (double-blind, placebo-controlled) testing
the efficacy and safeness of Afrin in comparison to a placebo group, were found using the
PubMed database.
OUTCOMES MEASURED: Nasal patency, congestion, degree of nasal blockage, and symptoms
(quantity, consistency, color of nasal secretions, turbinate size/color) were measured through
patient diary card symptom scores, visual analogue scales, and clinical nasal visual
examinations.
RESULTS: The Morris et al and Watanabe et al studies found that the subjective measurements
and nasal examinations did not show clinically significant signs of rhinitis or differences
between treatment groups after using Afrin. A clinically significant decongestant effect of Afrin
was noted at each visit in all three RCT’s. Bickford et al reports that symptoms of congestion
decreased significantly after using Afrin but not after using the placebo. Morris et al and
Watanabe et al found no signs of increased tolerance to Afrin, but evidence of rebound nasal
congestion was reported after 3 days of Afrin treatment in the Morris study and no significant
rebound nasal congestion was discovered by Watanabe et al after 4 weeks treatment.
CONCLUSIONS: All three RCT’s showed that Afrin is effective in treating nasal congestion in
normal, healthy adults. After subjects were treated with various doses of Afrin nasal spray, no
clinically significant nasal congestion was found in any of the treatment groups. Morris et al and
Watanabe et al found that there was no tolerance to the medication after using repeated doses.
However, Morris et al found rebound nasal congestion after 3 days of use, whereas Watanabe et
al found no rebound congestion after using various doses of Afrin for 4 weeks. Further research
is needed to determine the appropriate length of treatment and possible side effects (rebound
congestion) of Afrin.
KEY WORDS: Afrin; Oxymetazoline; Nasal Congestion; Adults
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INTRODUCTION
Nasal congestion is an extremely common problem and complaint, affecting the majority
of the population including each gender, race and age group across the world. Due to the
numerous etiologies of nasal congestion and acute rhinitis, there are a myriad of treatment
options to help ameliorate this problem. Therefore, treatment decisions can become quite
difficult for both the consumer and provider. It is important to know which drugs not only
provide the best treatment and relief, but those that have minimal side effects and maximum
safety. This systematic review analyzes three placebo-controlled, double-blind, randomized
controlled trials in normal, healthy men and women, age 16 and above, in order to determine the
efficacy and safeness of Afrin (Oxymetazoline) with reference to nasal congestion and the nasal
response.
The prevalence of nasal congestion is increasing worldwide, now including more than
10-40% of the total population.1 In 2003, a Gallup poll found that >50% of Americans are
suffering from nasal congestion and will self medicate to relieve their symptoms.1 Allergic
rhinitis has been identified as the most common cause of nasal congestion, affecting at least 40
million (>20%) of Americans today.2 Around 1 in 7 adults (14%), >18 years of age, have been
diagnosed with allergies, with more than 60% of those patients reporting daily nasal congestion.1
“The apparent increase in the prevalence of allergic rhinitis in studies worldwide highlights the
need for more effective treatment options for allergic rhinitis…congestion in particular.”1
The economic impact of nasal congestion alone is currently unknown. Research focuses
primarily on the causes, most frequently allergic rhinitis and rhinosinusitis, which have nasal
congestion as their most common symptom.1 In 2011, $5.3 billion/year was estimated as the
total direct and indirect cost of allergic rhinitis alone.2 However, there are several other co-
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morbidities, such as asthma, that encompass nasal congestion as a symptom as well. The
increasing prevalence also increases the number of healthcare visits per year. In 2005, there
were more than 13 million office visits in which the patient presented with nasal congestion as a
chief complaint.1 In 2006, allergic rhinitis alone accounted for >12 million office visits per
year.1 These staggering numbers help to recognize the increased need for an effective and safe
fix.
Currently, many treatment options are available; however, both patients and providers
remain unsure as to which products are best. Current guidelines exist regarding the length of
treatment for nasal congestion with reference to rebound complications, but the precise
mechanism of rebound congestion, and other complications is still unknown.2 Different drugs
and the components within each treatment can lead to various side effects when used for
different periods of time and further research must still be conducted to determine which drugs
are most appropriate.2
The most commonly used treatments for nasal congestion include oral antihistamines,
decongestants, or both as needed.2 Depending on the source of the congestion, different
medications within certain classes are used. For example, an intranasal steroid spray is
frequently used in cases of chronic congestion.2 Other treatment options include: 2nd generation
antihistamines, intranasal antihistamine sprays, leukotriene receptor agonists, intranasal
Cromolyn, intranasal anticholinergic sprays, short courses of corticosteroids, and first generation
antihistamines.2 Afrin falls within the nasal decongestant class. It works by narrowing the blood
vessels within the nasal canal.2
The widespread usage of nasal decongestants like Afrin, has led to increasing concerns of
abuse, rebound complications such as nasal congestion, tachyphylaxis, and nasal mucosa
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swelling, tolerance, efficacy and safeness.3 The amount of time remains unclear as to how long a
nasal decongestant can be used for, and the correct dosage prior to developing undesirable
effects.3 Afrin is compared to placebos in various dosages over different periods of time in order
to determine its safety and efficacy, with reference to nasal congestion and the nasal response.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not, “Is Afrin
(Oxymetazoline) a safe and effective drug in normal, healthy adults with reference to nasal
congestion and the nasal response?” Recent studies have shown that Afrin is effective in treating
acute nasal congestion, but it remains unclear as to the correlation between prolonged use of the
drug and rebound complications.
METHODS
Certain criteria were used to select similar studies in order to obtain more specific,
accurate results. Each study selected focused on a population consisting of normal, healthy adult
men and women 16 years of age or older. All three articles concentrated upon the intervention
Afrin (Oxymetazoline), a topical decongestant nasal spray, and compared the effects of Afrin at
varying dosages to the effects of a placebo. Morris et al3 is a double-blind, placebo- controlled
randomized controlled trial that studied 7 days of Afrin (0.05%) nasal spray treatment in subjects
that received either daily Afrin (0.05%), intermittent Afrin (0.05%) morning doses on days 1, 3,
and 7 with all other doses placebo, or daily placebo doses for comparison. Bickford et al4 is a
double-blind, placebo-controlled, randomized controlled trial and crossover study that focused
on the administration of Afrin nasal spray 0.5 mg ml-1 (0.9 mg to each nostril) in comparison to a
placebo nasal spray made of saline solution 0.9% to each nostril. Nasal patency measurements
were made up to an hour prior to medication delivery and up to 120 minutes post delivery. 4 The
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crossover was measured 7-21 days later.4 Watanabe et al5 is a double-blind, placebo-controlled
randomized controlled trial that used 0.05% Afrin nasal spray, 2 sprays (0.1 ml/spray) to each
nostril 3 times daily and compared it to a matched placebo nasal spray over a 4 week period. In
this study, both the Afrin and the placebo nasal spray contained the chemical benzalkonium
chloride 0.1%.5 Each study measured nasal patency, nasal congestion, degree of nasal blockage,
and symptoms including: quantity, consistency, color of nasal secretions, and turbinate size and
color.3,4,5
In order to successfully locate articles pertaining to Afrin’s efficacy and safeness with
similar subject populations, a detailed and refined search was conducted using the key words,
“Afrin,” “Oxymetazoline,” “Nasal congestion,” and “Adults.” Several databases were reviewed
including OVID, Medline, Cochrane and PubMed; however, the articles analyzed in this paper
were all located on the PubMed database. All selected articles are written in the English
language and published in peer-reviewed journals. To narrow down the selection, each article
was chosen based on relevance and patient-oriented evidence that matters (POEMS). Inclusion
criteria for article selection included: randomized controlled trials published after 1996, POEMS,
healthy adult patients >16 years of age, and minimal nasal airway resistance at baseline with
normal nasal anatomy. Exclusion criteria includes: subjects with a past medical history of
significant medical disease, seasonal allergies, nasal deformity/deviation, those who have taken
recent medications such as antihistamines or decongestants, those who have had a recent URI or
cold, and smokers. 3,4,5 The statistics reported are: p-values with a significant result <0.05,
change in mean from baseline, mean +/- SD3; CI interval, ANOVA, CV4; and RRR, ARR,
NNT5.
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Table 1: Demographics & characteristics of included studies for analysis of Afrin with reference
to nasal congestion and the nasal response:
Study

Type

# Pts

Morris3,
1997

RCT, double 50
blind,
placebo
controlled

Bickford4,
1999

RCT, double 20
blind,
placebo
controlled
crossover
study

Watanabe5, RCT, double 30
blind,
2003
placebo
controlled

Age

Inclusion Exclusion Criteria W/D
Criteria
18-59 50 healthy NAR on day 1 >0.3 N/A
subject
Pa/cm3/s, hx of
volunteers alcohol/ drug abuse;
between 18- hx of any significant
59, male or disease; rhinitis;
female
deviated nasal
septum, polyps, etc;
not on current
medications
affecting nasal
congestion; smoker;
pregnant
18+
20 healthy All subjects free of 0
mean adult
URI and no
27.3 volunteers, evidence of
male or
pharyngeal
female;
erythema, anatomic
minimal
nasal
baseline
obstruction/deformit
NAR of at y; no sx of nasal
least 0.15 congestion; could
Pa/s/cm-3 not have taken meds
which may have
influenced nasal
congestion or
interacted with
Afrin
16-60 Negative hx Current smokers,
0
of seasonal/ taking concurrent
perennial medication, hx of
nasal sx
use of topical or
other than systemic nasal
common
vasoconstrictors in
cold, non- last 6 months, hx of
smokers,
URI in last 4 wks,
normal lung pmh of htn, CVD, or
function,
other significant
normal
medical problems
nasal
anatomy

Interventions
7 days tx with
Oxymetazoline
(0/05% w/v) nasal
spray; randomized
to receive either
daily(0.05%) or
intermittent (0.05%
with morning doses
on days 1,3,7 and
all other doses
placebo)
Nasal Spray
Oxymetazoline 0.5
mg ml -1(0.9 mg to
each nostril)
compared to nasal
spray placebo
(saline solution
0.9%) to each
nostril

0.05%
Oxymetazoline
Nasal Spray: 2
sprays (0.1
ml/spray) to each
nostril 3x daily
over extended
period of 4 weeks
in comparison to
placebo nasal spray
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OUTCOMES MEASURED
Both the patient and clinician measured outcomes in order to determine symptoms of
nasal congestion, blockage or patency. Morris et al3 utilized subjective scaling of nasal patency
through a visual analogue scale (VAS) and through a clinical examination by a physician.
Bickford et al4 also measured the outcomes through a 100-mm visual analogue scale with
descriptors ranging from “nose completely clear,” to “nose completely blocked,” representing
values of 0 and 100 mm respectively. Watanabe et al5 had subjects complete a diary card of
nasal symptoms and undergo a clinical examination. The card included: nasal blocking (scale 04), 0= no symptoms, 1=mild blockage, 2= moderate blockage, 3=severe blockage, 4= complete
nasal blockage.5
RESULTS
The results pertaining to the primary outcome were presented as continuous data in all
three studies. The continuous data presented in both the Morris et al 3 and Bickford et al4 studies
was unable to be changed into dichotomous form; however, the data presented in Watanabe et al5
could be converted.
The Morris et al 3 RCT assessed the nasal response in 50 subjects after 7 days of Afrin
regimes, by measuring nasal airway resistance (NAR) subjectively through a visual analogue
scale (VAS) and clinical examination. The VAS and NAR subjective results were similar
throughout the study with no separation between the treatment groups. Day 1 results (Table 2)
illustrated a significant decongestant effect (p < 0.05) which occurred 30 minutes after drug
administration and continued for up to 6 hours in both the daily and intermittent groups.
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Table 2: Mean NAR change in baseline before and after treatment on Day 1:
Mean NAR Pre Tx

Mean NAR Post Tx

Daily Afrin Tx Group

0.23 + 0.05 Pa/cm3 /s

0.15 + 0.04 Pa/cm3 /s

Intermittent Afrin Tx Group

0.22 + 0.07 Pa/cm3/s

0.15 + 0.04 Pa/cm3 /s

Placebo Group

0.26 + 0.09 Pa/cm3 /s

0.39 + 0.35 Pa/cm 3 /s

However, the change in baseline of the mean NAR for the placebo group increased significantly
(p<0.05). 3 The change from baseline was higher on Day 3 and 7 than on Day 1 for the daily
and intermittent groups. Oxymetazoline remained effective at reducing the NAR throughout all
7 days, showing its significant decongestant effect without the development of a drug tolerance. 3
Table 3: Mean Baseline NAR on Day 1 and Day 3 for Daily and Intermittent Treatment Groups:
Daily: Baseline NAR

Intermittent: Baseline NAR

Day 1

0.23 + 0.05 Pa/cm3/s

0.22 + 0.07 Pa/cm3/s

Day 3

0.38 + 0.23 Pa/cm3/s

0.31 + 0.15 Pa/cm3/s

The significant change in mean baseline (p<0.05) in both the daily and intermittent groups
indicates rebound congestion. The trend continued on to Day 7 but it was not statistically
significant. The NAR baseline in placebo group also increased; however, it did not reach
statistical significance as well. After treatment was completed, the intermittent group was the
only group with significantly higher NAR on days 8 and 9 in comparison to day 1 (p <0.05).3
Bickford et al 4, a crossover trial, assessed symptoms of congestion through a visual
analogue scale (CON, range 0-100) and the results were illustrated by the AUC showing a
change from baseline value. When referring to the efficacy variables, the baseline values were
similar on both days of the crossover studies. The nasal airway resistance (NAR) and subjective
CON values indicating symptom scores, remained unchanged after the placebo, but fell
significantly after the Oxymetazoline at all times 2 hours post dosing. Both the NAR AUC and
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the CON AUC showed significant differences between the Oxymetazoline and placebo groups,
P< 0.001 and P= 0.012 respectively.4
Watanabe et al5 is a randomized double-blind, placebo-controlled continuous study in
which its data is capable of being converted into dichotomous format (see Table 4). The
treatment effects were analyzed using the Wilcoxon rank test. At baseline, nasal patency
between the treatment groups was not statistically different and groups were matched for gender,
baseline lung function and atopic status. After subjective diary symptom scores and clinical
exams were completed post Oxymetazoline challenge, the results did not show a significant
increase in subjective nasal blockage after 4 weeks of usage and 6 weeks of total monitoring for
the Oxymetazoline or placebo groups. There was also a highly significant decongestant effect
after each Oxymetazoline treatment. However, the subject diary symptom scores were unable to
be analyzed numerically because the majority of the results showed a 0, indicating “no blockage”
for both treatment groups at all points throughout the study. A possible trend in the placebo
group was developing, showing mild and occasionally moderate nasal blockage but it was not
significantly different between the groups. The clinical examination did not find significant
changes in the nasal mucosa appearance, significant bleeding, or findings associated with rhinitis
medicamentosa in either group. 5 Table 4 uses the evening measurements at the end of the 4
week treatment period, to analyze the outcome of nasal congestion for prevention.
Table 4: Analysis of RRR and NNT for Prevention in the Watanabe et al5 study:
Control Event Rate
(CER)

Experimental
Event Rate (EER)

Relative Risk
Reduction (RRR)

Absolute Risk
Reduction (ARR)

Number Needed to
Treat (NNT)

67%

93%

38.8%

26%

4

The NNT illustrates that for every 4 patients that are treated, 1 patient will be symptom free,
therefore preventing a negative outcome such as worsening of symptoms or complications, when
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compared to a placebo at 4 weeks. However, negative outcomes were not significant in this
study.
Due to the limited adverse effects of Afrin and the lack of complications within all 3
studies, each study had a 100% compliance rate. On clinical exam, changes in the nasal mucosa
were not found in any of the studies, and trends of rebound congestion were noted to be the only
adverse effect found when using Afrin in healthy, normal adults.3,4,5
DISCUSSION
Afrin is one of the most commonly used medications to treat nasal congestion; however,
the general population associates prolonged use of this medication with rebound effects and
complications. According to Morris et al3, prior studies have focussed on weeks, months or
years of decongestant use and little research has been published on Afrin use for shorter periods
of time. In 1985, the FDA recommended that decongestant products such as Afrin should be
used for a maximum of 3 days and stated that these medications produce rebound congestion
within hours of use.3 However, their recommendation centered upon long term Afrin use in
studies conducted more than 30 years ago. Current literature focussing upon short term
decongestant use and its possible rebound effects remains unclear.
According to PubMedHealth6, recent guidelines suggest using Afrin nasal spray every
10-12 hours as needed but no more than twice in a 24 hour period. Users are instructed to use
the spray for no more than 3 days consecutively and a warning is given that if the drug is used
for longer than the recommended period of time, the congestion can worsen, improve, or come
back. Possible side effects include: burning, stinging, increased nasal discharge, dryness inside
the nose, sneezing, nervousness, nausea, dizziness, headache, difficulty falling asleep or staying
asleep, fast heartbeat or slow heartbeat.6
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When referring to efficacy, Morris et al3 showed that Afrin was just as effective in
reducing the NAR on day 1 as on day 7 and Watanabe et al5 found no significant increases in
subjective nasal blockage after 4 weeks of treatment and for 2 weeks after discontinuation of the
drug. All three studies found a highly significant decongestant effect, therefore indicating that
not only is Afrin effective in eliminating nasal congestion, but Afrin does not cause a drug
tolerance to develop after continual doses.
The safety of this drug remains unclear because some evidence, as seen in Morris et al3,
shows that Afrin may cause rebound congestion after 3 days of treatment, but Watanabe et al5
found no evidence of rebound congestion or other side effects after 4 weeks of continuous
dosing. In the Morris et al3 study, the baseline NAR on day 3 was significantly greater than day
1 in both the daily and intermittent groups, but the baseline NAR differences between the
treatment and placebo groups did not reach significance on any of the days. However, the
rebound congestion on day 3 cannot be attributed to Afrin use alone because the baseline NAR
increased over the course of the study in both the treatment and placebo groups. It is possible that
the benzalkonium chloride in the placebo contributed to the rebound congestion by acting as a
nasal irritant and reducing mucociliary clearance.3
While Morris et al3 and Watanabe et al5 recruited volunteers without a baseline nasal
airway resistance, the Bickford et al4 study used participants with a minimal NAR baseline, but
still within the normal range, to increase the ability of detecting a significant decrease in NAR.
In the Bickford et al4 study, Afrin showed a significant decongestant effect in the subjective
results that was further verified by parallel results of the objective measurements.4
Possible limitations to help explain variability within results include small sample sizes,
the use of irritants and various substances in some of the placebo sprays, and subjective scaling.
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It is possible that spraying a placebo into the nasal canal can lead to rebound congestion and
further studies are needed to determine if the substances in the vehicle spray are responsible for
causing rebound side effects. Subjective scaling is also not the most accurate way to detect
congestion because perceptions of symptom severity can differ from person to person and
symptoms can be affected by sensory changes as well as changes in NAR.
CONCLUSION
All three randomized controlled trials demonstrated that Afrin is an effective treatment in
normal healthy adults with reference to nasal congestion and the nasal response. After subjects
were treated with various doses of Afrin over different periods of time, no evidence of significant
nasal congestion was found after continually using the drug, also showing that a tolerance to the
drug does not develop. However, there was conflicting evidence regarding drug safety and
appropriate length of treatment prior to developing side effects. Morris et al3 found rebound
congestion after 3 days of Afrin use, whereas Watanabe et al5 found no evidence of rebound
congestion after 4 weeks of use.
Future studies are warranted to determine the appropriate length of treatment, when side
effects occur, and if they even occur at all. Current studies often use placebos that contain
substances like benzalkonium chloride, which can lead to nasal congestion, possibly impacting
the validity of the results. Research is indicated to determine if these substances, which can be
found in both the placebo and Afrin nasal sprays, are causing rebound congestion. It is essential
that appropriate length of treatment and adverse side effects be fully understood to help those
who are suffering from nasal congestion feel that their symptoms are being treated adequately.
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